Roche to Acquire InterMune for $8.3 Billion

Home/Financial/Roche to Acquire InterMune for $8.3 Billion

Roche to Acquire InterMune for $8.3 Billion

Big bucks.

There have been rumors for a while of a possible acquisition of InterMune, and now it’s official: Roche will acquire InterMune for $8.3 billion, enabling Roche to expand its presence in the treatment of respiratory disorders, one of the world’s biggest drug markets.

Coverage thus far:

SF Business Times: Inside Roche’s $8.3 billion bid for InterMune

SFGate: Roche buys Brisbane drugmaker InterMune for $8.3 billion

Bloomberg: Roche Holding Agrees to Buy InterMune for $8.3 Billion

Reuters: Roche to buy U.S. biotech firm InterMune for $8.3 billion

Forbes: Roche CEO On Intermune Deal: ‘This Is A Growth Story’

Forbes: Roche’s InterMune Acquisition Underscores How It And Pfizer Are On Different M&A Paths

SV Business Journal: InterMune CEO: Bittersweet ending to this biotech comeback story

August 25th, 2014|